Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. and its partner Boehringer Ingelheim GmbH won the first-ever US approval of a follow-on version of Sanofi SA's Lantus (insulin glargine) – a clearance for marketing that was permitted under the FDA's 505(b)(2) abbreviated pathway, which permits an application to rely, in part, on safety and efficacy data from an innovator's product.

You may also be interested in...



Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.

Lilly Executes Growth Strategy As New Products Drive Sales Gains

Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.

1Q Earnings Preview: What To Expect From US, EU Big Hitters

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel